|
SAN FRANCISCO (AP) - Despite optimism and enthusiasm, stem cell researchers arriving here Thursday for a conference are rowing hard against strong currents of financial, political and technical turmoil.
There's even talk of trying to temper heightened public expectations that cures for diseases are imminent.
"Many of the technologies we hyped to the general public haven't worked yet," Celgene Corp. President Alan Lewis said Wednesday at a biotechnology trade show in Philadelphia. He also noted that venture capitalists "are very cautious" about investing in stem cell companies because of uncertainty over the field's future.
|